Clinical Drug Testing in Primary Care (TAP 32)

(4)
Clinical Drug Testing in Primary Care (TAP 32) image
ISBN-10:

1304146227

ISBN-13:

9781304146229

Edition: null
Released: Jun 17, 2013
Publisher: lulu.com
Format: Paperback, 93 pages

Description:

This Technical Assistance Publication (TAP), Clinical Drug Testing in Primary Care, is for clinical practitioners- physicians, nurse practitioners, and physician assistants- in health centers. The publication provides information that practitioners need when deciding whether to introduce drug testing in their practices and gives guidance on implementing drug testing. The TAP does not address drug testing for law enforcement or legal purposes, nor does it include testing for the use of anabolic steroids or performance-enhancing substances. This TAP describes some of the ways that drug testing can contribute to the assessment, diagnosis, and treatment of patients seen in primary care, the management of the treatment of chronic pain and the identification and treatment of substance use disorders.

Best prices to buy, sell, or rent ISBN 9781304146229




Frequently Asked Questions about Clinical Drug Testing in Primary Care (TAP 32)

You can buy the Clinical Drug Testing in Primary Care (TAP 32) book at one of 20+ online bookstores with BookScouter, the website that helps find the best deal across the web. Currently, the best offer comes from and is $ for the .

If you’re interested in selling back the Clinical Drug Testing in Primary Care (TAP 32) book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.

As for the Clinical Drug Testing in Primary Care (TAP 32) book, the best buyback offer comes from and is $ for the book in good condition.

The Clinical Drug Testing in Primary Care (TAP 32) book is in very low demand now as the rank for the book is 8,065,599 at the moment. A rank of 1,000,000 means the last copy sold approximately a month ago.

Not enough insights yet.